Extedo adds two to management board

Directors will be based in Germany and US respectively

Extedo, a provider of eRegulatory Affairs solutions to life sciences firms, has added Martin Schmid and Joseph Dude to its management board.

Schmid joins the organisation as president and now shares day-to-day operational responsibilities with chief executive Tore Bergsteiner.

Dude has taken the position of managing director at Extedo Inc in the US, to support the organisation’s expansion in North America.

Schmid will head up the global marketing and sales organisation as well as the Product Management Unit, which are key areas for Extedo. He will be based in Ottobrunn, Germany.

Schmid has more than 15 years of experience in management consulting, marketing and sales.

Dude will be based in West Chester, PA. He has more than 20 years of experience in the IT services and software industries with Prime Technology Group, Glemser Technologies, First Consulting Group and Thomson Financial.

You may also like

Regulatory

New NICE thresholds: good news for rare disease drugs but process remains complex

Recent changes introduced by NICE will ultimately see more ultra-rare disease drugs get to market, but Dan Williams, CEO at SynaptixBio, says the process remains challenging
Manufacturing

Balancing innovation and accessibility in amino acid testing

Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Quality management during manufacturing changes: part I

Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
Regulatory

Oncolytics Biotech announces positive clinical data for metastatic colorectal cancer trial

The latest results could accelerate the company's path to registration after the FDA's Breakthrough Therapy designations created momentum for companies advancing pioneering oncology platforms
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

From approval to access: the strategic role of packaging in drug launch success

In today’s increasingly complex pharmaceutical landscape, securing regulatory approval is only one milestone on the journey to market
Ingredients

FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars

The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs
Regulatory

Pfizer and BioNTech’s COMIRNATY COVID-19 vaccine wins FDA approval for seniors and high-risk individuals

The COVID-19 vaccines by Pfizer and BioNTech are based on BioNTech’s proprietary mRNA technology and were developed by both companies
Subscribe now